Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

Affiliations

• ¹ Dept. of Immunohematology and Blood Transfusion, Leiden University Medical Center and the Jon J van Rood Center for Clinical Transfusion Research, Sanquin-Leiden University Medical Center, The Netherlands j.j.zwaginga@lumc.nl.
• ² HOVON Data Center, Erasmus MC Cancer Institute - Clinical Trial Center, Rotterdam.
• ³ Dept. of Hematology, Erasmus MC, Rotterdam.
• ⁴ Dept. of Hematology, Academic Medical Center Amsterdam, The Netherlands.
• ⁵ Dept. of Internal Medicine, Albert Schweitzer Hospital, Dordrecht.
• ⁶ Department of Internal Medicine, Diakonessenhuis, Utrecht.
• ⁷ Dept. of Immunohematology and Blood Transfusion, Leiden University Medical Center and the Jon J van Rood Center for Clinical Transfusion Research, Sanquin-Leiden University Medical Center, The Netherlands.
• ⁸ Dept. of Hematology, VU University Medical Center, Amsterdam.
• ⁹ Dept. of Internal Medicine, Jeroen Bosch Hospital, Den Bosch.
• ¹⁰ Dept. of Hematology, Radboud University Medical Centre, Nijmegen.
• ¹¹ Dept of Internal Medicine, Máxima Medical Center, Veldhoven.
• ¹² Dept. of Internal Medicine, Medisch Spectrum Twente, Enschede.
• ¹³ Dept. of Internal Medicine, St. Antonius Hospital, Nieuwegein.
• ¹⁴ Dept. of Laboratory Medicine, Radboud University Medical Center, Nijmegen.
• ¹⁵ Dept. of Internal Medicine, Westfriesgasthuis, Hoorn.
• ¹⁶ Dept. of Internal Medicine, Meander Hospital, Amersfoort.
• ¹⁷ Dept. of Internal Medicine, HagaZiekenhuis, Den Haag.
• ¹⁸ Dept. of Internal Medicine, Tergooiziekenhuizen, Blaricum.
• ¹⁹ Waterland hospital, Purmerend.
• ²⁰ Dept. of Internal Medicine, Spaarne hospital, Hoofddorp.
• ²¹ Dept. of Internal Medicine, Lievensberg Hospital, Bergen op Zoom, The Netherlands.
• ²² Dept. of Internal Medicine, Gelderse Vallei Hospital, Ede, The Netherlands.